Polyclonal antibody targeting HA for IPP.
| Product Specifications | |
| Application | IP |
| Clonality | Polyclonal |
| Host | Rabbit |
| Formulation | 540 mg of anti-HA Tag polyclonal antibody covalently coupled to 200 uL of agarose gel and provided as a 50% gel slurry suspended in PBS containing preservative (0.09% sodium azide) for a total volume of 400 uL. |
| Citations for Anti-HA-tag pAb-Agarose – 2 Found |
| Ogi, Tomoo; Walker, Sarah; Stiff, Tom; Hobson, Emma; Limsirichaikul, Siripan; Carpenter, Gillian; Prescott, Katrina; Suri, Mohnish; Byrd, Philip J; Matsuse, Michiko; Mitsutake, Norisato; Nakazawa, Yuka; Vasudevan, Pradeep; Barrow, Margaret; Stewart, Grant S; Taylor, A Malcolm R; O'Driscoll, Mark; Jeggo, Penny A. Identification of the first ATRIP-deficient patient and novel mutations in ATR define a clinical spectrum for ATR-ATRIP Seckel Syndrome. Plos Genetics. 8(11):e1002945. PubMed - Comments: Used in: IP |
| Saito, Ken; Iioka, Hidekazu; Maruyama, Satoshi; Sumardika, I Wayan; Sakaguchi, Masakiyo; Kondo, Eisaku. PODXL1 promotes metastasis of the pancreatic ductal adenocarcinoma by activating the C5aR/C5a axis from the tumor microenvironment. Neoplasia (New York, N.y.). 2019;21(12):1121-1132. PubMed - Comments: Used in: IP |